Abstract
Bowman-Birk inhibitors and their variants (BBI) from legumes, such as soybean, pea, lentil and chickpea, are a class of naturally-occurring protease inhibitors which have potential health-promoting properties within the gastrointestinal tract. BBI can resist both acidic conditions and the action of proteolytic enzymes, and transit through the stomach and small intestine without major degradation, permitting significant amounts to reach the large intestine in active form to exert their reported anti-carcinogenic and anti-inflammatory properties. These potential pharmacological benefits have been linked recently to the intrinsic ability of BBI to inhibit serine proteases, and the data suggest that both trypsin- and chymotrypsin- like proteases involved in carcinogenesis should be considered as potential targets of BBI. However, the therapeutic targets and the action mechanisms of BBI remain unknown. Their elucidation will provide insights into the properties of these plant protease inhibitors as colorectal chemopreventive agents, providing a strong base for the development of legume crops and their products as pro-nutritional, health-promoting food. The deployment of modern genomic tools and genome sequence information are underpinning studies of natural and induced polymorphism in BBI. Genetic markers for BBI variants with improved properties can be exploited ultimately in legume breeding programmes to assist the introgression of such variant genes and the development of superior genotypes for human nutrition.
Keywords: Bowman-Birk inhibitors, chemoprevention, colorectal cancer, legumes, serine proteases, human nutrition, legume breeding, chymotrypsin-like proteases, trypsin-like proteases, dietary proteins, lectins, chemopreventive agents, FDA, amino acid sequence
Current Protein & Peptide Science
Title: Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Volume: 12 Issue: 5
Author(s): Alfonso Clemente, Gabriella Sonnante and Claire Domoney
Affiliation:
Keywords: Bowman-Birk inhibitors, chemoprevention, colorectal cancer, legumes, serine proteases, human nutrition, legume breeding, chymotrypsin-like proteases, trypsin-like proteases, dietary proteins, lectins, chemopreventive agents, FDA, amino acid sequence
Abstract: Bowman-Birk inhibitors and their variants (BBI) from legumes, such as soybean, pea, lentil and chickpea, are a class of naturally-occurring protease inhibitors which have potential health-promoting properties within the gastrointestinal tract. BBI can resist both acidic conditions and the action of proteolytic enzymes, and transit through the stomach and small intestine without major degradation, permitting significant amounts to reach the large intestine in active form to exert their reported anti-carcinogenic and anti-inflammatory properties. These potential pharmacological benefits have been linked recently to the intrinsic ability of BBI to inhibit serine proteases, and the data suggest that both trypsin- and chymotrypsin- like proteases involved in carcinogenesis should be considered as potential targets of BBI. However, the therapeutic targets and the action mechanisms of BBI remain unknown. Their elucidation will provide insights into the properties of these plant protease inhibitors as colorectal chemopreventive agents, providing a strong base for the development of legume crops and their products as pro-nutritional, health-promoting food. The deployment of modern genomic tools and genome sequence information are underpinning studies of natural and induced polymorphism in BBI. Genetic markers for BBI variants with improved properties can be exploited ultimately in legume breeding programmes to assist the introgression of such variant genes and the development of superior genotypes for human nutrition.
Export Options
About this article
Cite this article as:
Clemente Alfonso, Sonnante Gabriella and Domoney Claire, Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives, Current Protein & Peptide Science 2011; 12 (5) . https://dx.doi.org/10.2174/138920311796391133
DOI https://dx.doi.org/10.2174/138920311796391133 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Artificial Intelligence for Protein Research
Protein research, essential for understanding biological processes and creating therapeutics, faces challenges due to the intricate nature of protein structures and functions. Traditional methods are limited in exploring the vast protein sequence space efficiently. Artificial intelligence (AI) and machine learning (ML) offer promising solutions by improving predictions and speeding up ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein Folding, Aggregation and Liquid-Liquid Phase Separation
Protein folding, misfolding and aggregation remain one of the main problems of interdisciplinary science not only because many questions are still open, but also because they are important from the point of view of practical application. Protein aggregation and formation of fibrillar structures, for example, is a hallmark of a ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Topical Chemoprevention of Skin Cancers with Phytochemicals
Current Cancer Therapy Reviews Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Editorial [Hot Topic:Recent Advances in Molecular Targeting of Head and Neck Cancer (Guest Editor: Dong Moon Shin, M.D.)]
Current Cancer Drug Targets Gold Nanoparticles: Promising Agent to Improve the Diagnosis and Therapy of Cancer
Current Drug Metabolism Tumor Initiating Cells
Current Pharmaceutical Biotechnology Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets Percutaneous Dilatational Tracheostomy - An Update
Current Respiratory Medicine Reviews Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Recent Patents on Regenerative Medicine The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews Quantitative Structure-Wavelength Relationship Modeling of Porphin -Derivative Photosensitizers
Combinatorial Chemistry & High Throughput Screening Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Current Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Oncolytic Viruses for Induction of Anti-Tumor Immunity
Current Pharmaceutical Biotechnology Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry